US 12,226,468 B2Granted

Immunoreactive peptides

AssigneeResearch Development Foundation

InventorsJere McBride, David Walker

Life of this patent

Estimating the term…

Abstract

Immunoreactive engineered polypeptides are provided. The engineered polypeptides can be used to diagnose or induce an immune response against E. chaffeensis or E. canis.

Claims29

Dependent claims

An immunoreactive polypeptide comprising SEQ ID NO:1 or SEQ ID NO:7, or a polypeptide at least 90% identical thereto.

Dependencies are inferred from the claim text.

Facts

Application: 18/754,918Filed 26 Jun 2024 · us provisional application
Priority: 26 Jun 2023
Published: US 2024/0424075 A126 Dec 2024
Granted: 18 Feb 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 39/0233
Bacterial antigens: rickettsiales, e.g. Anaplasma
A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
C07K 14/29
From bacteria: from Richettsiales
G01N 33/56911
For microorganisms, e.g. protozoa, bacteria, viruses: bacteria

Family

Application63/510,310Us provisional application · filed 26 Jun 2023
US 2024/0424075 A1Pre-grant publication · published 26 Dec 2024
US 12,226,468 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…